NYSCF and Google Research integrate capabilities for disease profiling

2 min read

A robotic system for studying patient cells has been integrated with AI image analysis to create a new platform for discovering cellular signatures of disease including Parkinson’s. 

(Image: AdobeStock)

Using their automated cell culture platform, scientists at the NYSCF (New York Stem Cell Foundation) Research Institute collaborated with Google Research to identify new cellular hallmarks of Parkinson’s disease by creating and profiling over a million images of skin cells from a cohort of 91 patients and healthy controls. Their findings are detailed in Nature Communications.

“Traditional drug discovery isn’t working very well, particularly for complex diseases like Parkinson’s,” NYSCF CEO Susan L. Solomon, JD said in a statement. “The robotic technology NYSCF has built allows us to generate vast amounts of data from large populations of patients and discover new signatures of disease as an entirely new basis for discovering drugs that actually work.”


The study utilised NYSCF’s repository of patient cells and robotic system – The NYSCF Global Stem Cell Array – to profile images of millions of cells from 91 Parkinson’s patients and healthy controls.

Scientists used the Array to isolate and expand skin cells (fibroblasts) from skin punch biopsy samples, label different parts of these cells with a technique called Cell Painting, and create thousands of high-content optical microscopy images. The resulting images were fed into an artificial intelligence–driven image analysis system, identifying image features specific to patient cells that could be used to distinguish them from healthy controls.

“These artificial intelligence methods can determine what patient cells have in common that might not be otherwise observable,” said Samuel J. Yang, a research scientist at Google Research. “What’s also important is that the algorithms are unbiased - they do not rely on any prior knowledge or preconceptions about Parkinson’s disease, so we can discover entirely new signatures of disease.”

According to NYSCF, the need for new signatures of Parkinson’s is underscored by the high failure rates of recent clinical trials for drugs discovered based on specific disease targets and pathways believed to be drivers of the disease. The discovery of these novel disease signatures using unbiased methods, particularly across patient populations, has value for diagnostics and drug discovery, and can highlight new distinctions between patients.

“Excitingly, we were able to distinguish between images of patient cells and healthy controls, and between different subtypes of the disease,” said Bjarki Johannesson, PhD, a NYSCF senior investigator on the study. “We could even predict fairly accurately which donor a sample of cells came from.”

The Parkinson’s disease signatures identified by the team can now be used as a basis for conducting drug screens on patient cells, to discover which drugs can reverse these features. The study also yields the largest known Cell Painting dataset (48TB) as a community resource and is available to the research community.

The platform is disease-agnostic and only requires easily accessible skin cells from patients. It can also be applied to other cell types, including derivatives of induced pluripotent stem cells that NYSCF creates to model a variety of diseases.

“This is an ideal demonstration of the power of artificial intelligence for disease research,” said Marc Berndl, a software engineerat Google Research. “We have had a very productive collaboration with NYSCF, especially because their advanced robotic systems create reproducible data that can yield reliable insights.”